



## Model List of Essential Medicines



### Amikacin [General information](#)

#### Section

##### Access group antibiotics

- Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

#### Indications

#### First choice

[Neutropenia \(high-risk\)](#) co-prescribed with [cefotaxime Inflammatory and other diseases of prostate \(severe\)](#) co-prescribed with [cefotaxime Acute pyelonephritis \(severe\)](#) co-prescribed with [ceftriaxone Inflammatory and other diseases of prostate \(severe\)](#) co-prescribed with [ceftriaxone Acute pyelonephritis \(severe\)](#)



### Amoxicillin [General information](#)

#### Section

##### Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

#### Indications

#### First choice

[Acute pharyngitis](#) [Periapical abscess without sinus](#) [Acute sinusitis](#) [Acute otitis media](#) [Chronic obstructive pulmonary disease with acute exacerbation](#) [Acute malnutrition in infants, children or adolescents \(uncomplicated\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) [Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [gentamicin Sepsis without septic shock](#)

#### Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#) [Infectious cystitis](#)



#### **Amoxicillin + clavulanic acid** [General information](#)

##### Section

##### Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

##### Indications

##### First choice

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Infectious cystitis](#) [Acute sinusitis](#) [Neutropenia \(low-risk\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Bacterial cellulitis, erysipelas or lymphangitis](#) [Chronic obstructive pulmonary disease with acute exacerbation](#) [Peritonitis \(mild-moderate\)](#) [Peritoneal abscess \(mild-moderate\)](#)

##### Second choice

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Osteomyelitis or osteitis](#) [Bacterial infection of joint](#) [Other specified prophylactic measures](#) [Acute otitis media](#)

##### Other indications

[Bacterial infection of unspecified site](#)



#### **Ampicillin** [General information](#)

##### Section

##### Access group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
- Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

##### Indications

##### First choice

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [gentamicin](#) [Sepsis without septic shock](#)

##### Second choice

[Bacterial meningitis](#)

##### Other indications

[Bacterial infection of unspecified site](#)



#### **Benzathine benzylpenicillin** [General information](#)

##### Section

##### Access group antibiotics

- Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection

##### Indications

##### First choice

[Congenital syphilis \[children\]](#) [Syphilis](#)

##### Other indications

[Bacterial infection of unspecified site](#)



## **Benzylpenicillin** [General information](#)

### Section

#### Access group antibiotics

- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

#### Indications

##### **First choice**

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Congenital syphilis \[children\]](#) [Syphilis](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [gentamicin](#) [Sepsis without septic shock](#)

##### **Second choice**

[Bacterial meningitis](#)

#### Other indications

[Bacterial infection of unspecified site](#)

## **Cefalexin** [General information](#)

### Section

#### Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid: 250 mg (as monohydrate)
- Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
- Oral > Solid > dispersible tablet: 125 mg; 250 mg

#### Indications

##### **First choice**

[Bacterial cellulitis, erysipelas or lymphangitis](#)

##### **Second choice**

[Chronic obstructive pulmonary disease with acute exacerbation](#) [Acute pharyngitis](#)

#### Other indications

[Bacterial infection of unspecified site](#)

## **Cefazolin** [General information](#)

### Section

#### Access group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

#### Indications

##### **First choice**

[Other specified prophylactic measures](#) [Other specified prophylactic measures](#)

##### **Second choice**

[Bacterial infection of joint](#) [Osteomyelitis or osteitis](#)

#### Other indications

[Surgical site infection](#)

## **Chloramphenicol** [General information](#)

### Section

#### Access group antibiotics

- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
- Oral > Liquid: 150 mg per 5 mL (as palmitate)
- Oral > Solid: 250 mg capsule

Indications

**Second choice**

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

**Clindamycin** [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride) capsule
- Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
- Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
- Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)

Indications

**First choice**

[Necrotising fasciitis](#)

**Second choice**

[Bacterial infection of joint Osteomyelitis or osteitis](#)

Other indications

[Bacterial infection of unspecified site](#)

**Cloxacillin** [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
- Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
- Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

Indications

**First choice**

[Osteomyelitis or osteitis Bacterial infection of joint Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

[Sepsis without septic shock](#)

Other indications

[Bacterial infection of unspecified site](#)

**Dicloxacillin** [General information](#)

Section

Access group antibiotics

Indications

**First choice**

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

### **Doxycycline** [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
- Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
- Oral > Solid > dosage form: 100 mg (as hyclate)

Indications

**First choice**

[Cholera](#) [Chlamydia trachomatis](#)

**Second choice**

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Cholera \[children\]](#) [Chronic obstructive pulmonary disease with acute exacerbation](#)

Other indications

[Bacterial infection of unspecified site](#)

### **Flucloxacillin** [General information](#)

Section

Access group antibiotics

Indications

**First choice**

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

### **Gentamicin** [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

**First choice**

[Neonatal meningitis](#) [Sepsis without septic shock](#) [Sepsis without septic shock](#) [Sepsis without septic shock](#) co-prescribed with [amoxicillin](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [ampicillin](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [ampicillin](#) [Peritonitis \(mild-moderate\)](#) co-prescribed with [ampicillin](#) [Peritonitis \(severe\)](#) co-prescribed with [ampicillin](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ampicillin](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [ampicillin](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [benzylpenicillin](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [benzylpenicillin](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

**Second choice**

[Gonococcal infection](#) [Other specified prophylactic measures](#)

Other indications

[Bacterial infection of unspecified site](#)

### **Meticillin** [General information](#)

Section  
Access group antibiotics  
Indications

**First choice**

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

**Metronidazole [General information](#)**

Section  
Access group antibiotics

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg

Indications

**First choice**

[Trichomoniasis](#) [Intestinal infections due to Clostridioides difficile](#) [Necrotising fasciitis](#) co-prescribed with [cefazolin](#) [Other specified prophylactic measures](#) co-prescribed with [cefotaxime Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [cefotaxime Peritoneal abscess \(severe\)](#) co-prescribed with [cefotaxime Peritonitis \(mild-moderate\)](#) co-prescribed with [cefotaxime Peritonitis \(severe\)](#) co-prescribed with [ceftriaxone Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ceftriaxone Peritoneal abscess \(severe\)](#) co-prescribed with [ceftriaxone Peritonitis \(mild-moderate\)](#) co-prescribed with [ceftriaxone Peritonitis \(severe\)](#)

**Second choice**

co-prescribed with [ciprofloxacin Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ciprofloxacin Peritonitis \(mild-moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)

**Nafcillin [General information](#)**

Section  
Access group antibiotics  
Indications

**First choice**

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

**Nitrofurantoin [General information](#)**

Section  
Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

**First choice**

[Infectious cystitis](#)

### **Oxacillin [General information](#)**

Section

Access group antibiotics

Indications

**First choice**

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

### **Phenoxyethylpenicillin [General information](#)**

Section

Access group antibiotics

- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt) tablet
- Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

**First choice**

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Periapical abscess without sinus](#) [Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

### **Procaine benzylpenicillin [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

**First choice**

[Congenital syphilis \[children\]](#)

**Second choice**

[Syphilis](#)

### **Spectinomycin [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

Indications

**Second choice**

[Gonococcal infection](#)

Other indications

[Bacterial infection of unspecified site](#)

### **Sulfamethoxazole + trimethoprim [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10

mL ampoule

- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
- Oral > Solid > dispersible tablet: 100 mg + 20 mg

Indications

**First choice**

[Infectious cystitis](#)

**Second choice**

[Infectious gastroenteritis or colitis without specification of infectious agent](#)

Other indications

[Bacterial infection of unspecified site](#)

**Tetracycline** [General information](#)

Section

Access group antibiotics

- Oral > Solid: 250 mg (hydrochloride)

Indications

[Bacterial infection of unspecified site](#)

**Trimethoprim** [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 100 mg; 200 mg

Indications

**First choice**

[Infectious cystitis](#)